Tirzepatide vs Retatrutide
Retatrutide (sometimes called "reta" or the "triple agonist") is Eli Lilly's next-generation drug that targets three receptors instead of two. Early trial data shows weight loss numbers never seen before in pharmaceutical history. But it's not on the market yet. Here's how it stacks up against tirzepatide, which is available today.
“Retatrutide is showing the most impressive weight loss numbers in clinical history (~24% body weight), but it's not yet FDA-approved. Tirzepatide is available now and produces excellent results (20–22%). Unless you're in a trial or working with a cutting-edge clinic, tirzepatide is the smart choice today — with the option to switch when retatrutide receives approval.”
Tirzepatide
FDA ApprovedDual GLP-1 + GIP agonist. Two receptor targets produce stronger appetite suppression than semaglutide alone.
Retatrutide
Phase 3 TrialsTriple GLP-1 + GIP + Glucagon receptor agonist. The glucagon addition accelerates fat metabolism further.
Head-to-Head Comparison
Who Should Choose Which?
Choose Tirzepatide if…
- Available now — no waiting
- Proven efficacy in large trials
- FDA-approved — insurance eligible
- Sleep apnea
Choose Retatrutide if…
- People who want the most weight loss possible
- Those willing to wait for approval (est. 2026–2027)
- Clinical trial participants
Side Effects
Tirzepatide
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Fatigue
Retatrutide
- Similar GI profile to tirzepatide
- Nausea
- Vomiting
- Diarrhea
- Heart rate increase (notable side effect)
Frequently Asked Questions
What is retatrutide?
Retatrutide is Eli Lilly's experimental triple-agonist drug that targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed approximately 24% body weight loss at 48 weeks — the most in pharmaceutical history. Phase 3 trials are ongoing as of 2026.
When will retatrutide be FDA approved?
Eli Lilly has not provided a definitive timeline, but based on phase 3 trial progress, a 2026 or 2027 approval is plausible. This is not guaranteed — regulatory timelines can shift.
Should I wait for retatrutide instead of starting tirzepatide?
For most people, starting tirzepatide now is the better choice. Weight loss is a time-sensitive health issue. If retatrutide is approved later, switching is straightforward. The 2–4% difference in average weight loss doesn't justify delays of 1–2 years for most patients.
Is retatrutide available as a peptide?
Some research chemical suppliers label compounds as "retatrutide peptide" but these are not the same product used in Eli Lilly's trials and have no verified safety or efficacy data. We do not recommend sourcing retatrutide outside of an FDA-approved trial or licensed clinic.
Will tirzepatide still be prescribed after retatrutide is approved?
Almost certainly yes. Different patients respond differently to drugs, and tirzepatide's longer safety track record, established compounding market, and insurance coverage will keep it highly relevant even after retatrutide approval.
Your feedback helps us improve the guide.